Arcus Biosciences RCUS
NYSE RCUS
$24.46 -0.76 (-3.01%)
At close: Oct 2, 2026 · 4:00 PM EDT

Arcus Biosciences (RCUS) Asset Writedowns and Impairment (2024)

Updated

Arcus Biosciences (RCUS) posted Asset Writedowns and Impairment of $20 million for FY2024.

Analysis

Arcus Biosciences (RCUS) Asset Writedowns and Impairment (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Arcus Biosciences 3.11 Bn -229.58 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 20.00 Mn
API Access

Arcus Biosciences Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=RCUS&period=max&api_key=YOUR_API_KEY